Immunization of Mice
Maira-Litran et al – 2017 (view as PDF)...
Call:
+44 (0) 1865 784074
Oxford Vacmedix UK Limited:
Oxford, UK, OX4 4GA
Email:
enquiries@oxfordvacmedix.com
- Seeking Series B investment for next phase of clinical trials
Call:
+44 (0) 1865 784074
Oxford Vacmedix UK Limited:
Oxford, UK, OX4 4GA
Email:
enquiries@oxfordvacmedix.com
Publications
Survivin as a novel target protein for reducing the proliferation of cancer cells (Review)
Li, Hu and Li -2018 (view as PDF)...
Vaccination against HPV-16 Oncoproteins for Vulvar Intraepithelial Neoplasia
Kenter et al – 2009 (view as PDF)...
Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials
Johnson et al -2001 (view as PDF)...
Expression and clinical significance of survivin in ovarian cancer: A meta-analysis
He et al – 2018 (view as PDF)...
Guidance for Industry: Clinical Considerations for Therapeutic Cancer Vaccines
Guidance for Industry, Clinical Considerations for Therapeutic Cancer Vaccines (view as PDF)...
Contact Us
If you have any questions or want to get in touch, please contact our team.
(c) 2025 Oxford Vacmedix UK Limited | Company Registration: 07994205
English